Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Premarin Vaginal · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Premarin® Vaginal Cream | DRUG | - |
| Premarin® oral tablets | DRUG | - |
Inclusion Criteria: * Generally healthy postmenopausal women. * Intact uterus. * Clinical diagnosis of moderate to severe atrophic vaginitis.
Premarin Vaginal is used for atrophic vaginitis, a condition involving thinning and inflammation of the vaginal walls due to decreased estrogen. It is an investigational small molecule being developed by Pfizer, Inc. for this indication.
Premarin Vaginal contains conjugated estrogens, which work by replacing declining estrogen levels in the body. This helps restore the vaginal tissue and relieve symptoms of atrophic vaginitis.
Premarin Vaginal is developed by Pfizer, Inc., a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE.
Premarin Vaginal is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. One Phase 1 trial has been completed.
Premarin Vaginal has one completed clinical trial, NCT00167921, which compared Premarin Vaginal Cream versus Premarin Oral Tablets in atrophic vaginitis. The trial enrolled 24 female participants aged 45 years and older in the United States.
Premarin Vaginal is a specific vaginal cream formulation of Premarin, which is a brand name for conjugated estrogens. While both contain the same active ingredient, Premarin Vaginal is designed for local application to treat atrophic vaginitis.